Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation

Abstract Background The sodium–glucose cotransporter-2 (SGLT2) inhibitor canagliflozin has been shown to reduce major cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) especially in those with HF at baseline. These might indicate...

Full description

Bibliographic Details
Main Authors: Alex Ali Sayour, Sevil Korkmaz-Icöz, Sivakkanan Loganathan, Mihály Ruppert, Viktor Nabil Sayour, Attila Oláh, Kálmán Benke, Maik Brune, Rita Benkő, Eszter Mária Horváth, Matthias Karck, Béla Merkely, Tamás Radovits, Gábor Szabó
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Journal of Translational Medicine
Subjects:
Sodium–glucose cotransporter-2 inhibitor
Canagliflozin
Myocardial ischemia–reperfusion injury
Cardioprotection
Online Access:http://link.springer.com/article/10.1186/s12967-019-1881-8

Internet

http://link.springer.com/article/10.1186/s12967-019-1881-8

Similar Items